Atelvia Tablet, Delayed Release
Product Images NDC 0430-0979

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Atelvia (NDC 0430-0979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure For Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Atelvia Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Atelvia 01)

FDA Label Image

Figure 1 (Atelvia 02)

The text appears to be a caption for Figure 1. The figure likely shows the cumulative incidence of nonvertebral osteoporosis-related fractures over a 3-year period, comparing the placebo group to those taking either ACTONEL 5mg or a combination of VERT MN and VERT NA. The notation "[]" may indicate some additional information, but without further context, its meaning is not clear.*

FDA Label Image

Principal Display Panelndc 0430-0979-03atelvia 35 mg(risedronate Sodium) Delayed-release Tabletsonce-a-week4 Tabletsrx Only (Atelvia 03)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.